Real experiences of uHTS: a prototypic 1536-well fluorescence anisotropy-based uHTS screen and application of well-level quality control procedures.
This paper describes, for the first time, a true ultra-high throughput screen (uHTS) based upon fluorescence anisotropy and performed entirely in 1536-well assay plates. The assay is based upon binding and displacement of a BODIPY-FL-labeled antibiotic to a specific binding site on 70S ribosomes from Escherichia coli (Kd approximately 15 nM). The screen was performed at uHTS rates (i.e., >100,000 assay wells/24 h) using entirely commercially available equipment. In order to examine the reproducibility of detection of test compound effects, assays were performed in duplicate. Both overall assay statistics and reproducibility for individual compound results were excellent, at least equivalent to conventional HTS assays. Interference artifacts occurred mainly as a result of autofluorescence from test compounds. Well-level quality control procedures were developed to detect, eliminate, or even correct for such effects. Moreover, development of a brighter, longer wavelength probe (based upon Cy3B) markedly reduced such interferences. Overall, the data demonstrate that fluorescence anisotropy-based uHTS is now a practical reality.
Turconi
S
S
Molecular Interactions & New Assay Technologies, GlaxoSmithKline Pharmaceuticals, Harlow, Essex, UK.
Shea
K
K
Ashman
S
S
Fantom
K
K
Earnshaw
D L
DL
Bingham
R P
RP
Haupts
U M
UM
Brown
M J
MJ
Pope
A J
AJ
D000900:Anti-Bacterial Agents / Q000378:metabolism; D001665:Binding Sites; D001896:Boron Compounds; D004926:Escherichia coli / Q000648:ultrastructure; D005454:Fluorescence Polarization / Q000379:methods*; D005456:Fluorescent Dyes; D011786:Quality Control; D015203:Reproducibility of Results; D012270:Ribosomes / Q000378:metabolism
C095489:4,4-difluoro-4-bora-3a,4a-diaza-s-indacene; D000900:Anti-Bacterial Agents; D001896:Boron Compounds; D005456:Fluorescent Dyes